dc.contributor.author | Zhao, Huiping | |
dc.contributor.author | Blagg, Brian S. J. | |
dc.date.accessioned | 2017-05-04T18:04:41Z | |
dc.date.available | 2017-05-04T18:04:41Z | |
dc.date.issued | 2013-01-15 | |
dc.identifier.citation | Zhao, H., & Blagg, B. S. J. (2013). Novobiocin analogues with second-generation noviose surrogates. Bioorganic & Medicinal Chemistry Letters, 23(2), 552–557. http://doi.org/10.1016/j.bmcl.2012.11.022 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23891 | |
dc.description.abstract | Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C-terminal inhibitor ever identified and recent structure-activity relationship studies on the noviose sugar identified several commercially available amines as suitable surrogates. In an effort to further understand this region of the molecule, analogues containing various N′-amino substituents were prepared and evaluated against two breast cancer cell lines for determination of their efficacy. Compound 37j manifested the most potent anti-proliferative activity from these studies and induced Hsp90-dependent client protein degradation at mid nano-molar concentrations. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 United States (CC BY-NC-ND 3.0 US) License. | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us/ | en_US |
dc.subject | Heat shock protein 90 | en_US |
dc.subject | Hsp90 inhibitors | en_US |
dc.subject | Novobiocin analogues | en_US |
dc.subject | Breast cancer | en_US |
dc.title | Novobiocin analogues with second-generation noviose surrogates | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Zhao, Huiping | |
kusw.kuauthor | Blagg, Brian S. J. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
dc.identifier.doi | 10.1016/j.bmcl.2012.11.022 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC4123793 | en_US |
dc.rights.accessrights | openAccess | |